Musc Foundation for Research Development
9 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Recorded under 7 name spellings.
15
Ending by 2030
Jun 2027
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 2 fees due Jan 9 to 14, 2027 · next Jan 9
- 4 fees due Feb 6 to 27, 2027 · next Feb 6
- 4 fees due Apr 1 to 22, 2027 · next Apr 1
- 3 fees due May 7 to 21, 2027 · next May 7
- 2 fees due Jun 5 to 10, 2027 · next Jun 5
- 1 fee due Jul 30, 2027The maintenance fee for CD38-NAD+ Regulated Metabolic Axis in Anti-Tumor Immunotherapy (US 11,883,430) comes due Jul 30, 2027. Unpaid by Jan 31, 2028, it lapses early.
- 2 fees due Aug 16 to 27, 2027 · next Aug 16
- 3 fees due Sep 5 to 26, 2027 · next Sep 5
- 1 fee due Oct 23, 2027The maintenance fee for Activated CD26-HIGH Immune Cells and CD26-Negative Immune Cells and Uses Thereof (US 11,963,980) comes due Oct 23, 2027. Unpaid by Apr 24, 2028, it lapses early.
- 1 fee due Nov 7, 2027The maintenance fee for T Regulatory (Treg) Cell Transplantation in Osteogenesis Imperfecta (OI) (US 11,975,024) comes due Nov 7, 2027. Unpaid by May 8, 2028, it lapses early.
Recent changes
- 5 of the patents on this record were granted since Aug 17, 2026
- 9 terms have ended since Aug 17, 2026
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,759,304 | Targeting Complement Factor H for Treatment of Diseases In force · High confidence | In force | High confidence | |
| US 9,212,212 | Targeting Complement Factor H for Treatment of Diseases In force · Medium confidence | In force | Medium confidence | |
| US 8,735,365 | Targeting PAX2 for the Induction of DEFB1-MEDIATED Tumor Immunity and Cancer Therapy In force · Low confidence | In force | Low confidence | |
| US 8,623,617 | Detecting PAX2 for the Diagnosis of Breast Cancer In force (reinstated) · Low confidence | In force (reinstated) | Low confidence | |
| US 8,722,367 | Detecting PAX2 for the Diagnosis of Breast Cancer In force · Low confidence | In force | Low confidence | |
| US 8,241,905 | Self-Assembling Cell Aggregates and Methods of Making Engineered Tissue Using the Same In force · High confidence | In force | High confidence | |
| US 8,088,603 | Compositions and Methods for Diagnosing, Treating, and Preventing Prostate Conditions In force · High confidence | In force | High confidence | |
| US 8,569,225 | Targeting Complement Factor H for Treatment of Diseases In force · Medium confidence | In force | Medium confidence | |
| US 8,506,499 | Predicting Atrial Fibrillation Recurrence by Protease and Protease Inhibitor Profiling In force · High confidence | In force | High confidence | |
| US 8,489,186 | Devices and Methods for Treatment of Myocardial Conditions In force · High confidence | In force | High confidence |
Also on record, not counted in the 105: 9 patents in force now held by others · 78 lapsed for an unpaid fee · 38 ended at full term · 1 past the fee grace period · 1 surrendered on reissue. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
25 pending · 65 abandoned · 17 no status recorded